AbCellera Biologics Inc. (ABCL)

2.3900 -0.0400 (-1.65%) At close: 04:00PM EDT

AbCellera Biologics Inc.

2215 Yukon Street
Vancouver, BC V5Y 0A1
Canada
604 559 9005
https://www.abcellera.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 586

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Carl L.G. Hansen Ph.D.	CEO, President & Chairperson	714.94k	N/A	1975
Mr. Andrew Booth M.B.A.	Chief Financial Officer	674.55k	N/A	1974
Dr. Veronique Lecault Ph.D.	COO & Director	650.59k	1.41M	1985
Mr. Tryn T. Stimart Esq., J.D., M.Sc.	Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary & Privacy Officer	667.69k	N/A	1970
Marcie Thiessen CPA, CGA	Senior Director of Finance & Accounting	N/A	N/A	N/A
Dr. Ester Falconer Ph.D.	Chief Technology Officer	N/A	N/A	1975
Kathleen Reid B.A.	Head of Corporate Communications	N/A	N/A	N/A
Graham Craig M.Sc.	Director of Corporate Development	N/A	N/A	N/A
Mr. Murray McCutcheon Ph.D.	Senior Vice President of Partnering	N/A	N/A	N/A
Mr. Neil Aubuchon B.A., M.B.A.	Chief Commercial Officer	684.81k	N/A	1970

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Corporate governance

AbCellera Biologics Inc.’s ISS governance QualityScore as of 1 September 2024 is 8. The pillar scores are Audit: 8; Board: 9; Shareholder rights: 5; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.